[PDF] Top 20 Examen Parcial Gerencia Estrategica
Has 10000 "Examen Parcial Gerencia Estrategica" found on our website. Below are the top 20 most common "Examen Parcial Gerencia Estrategica".
Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
... to understand whether the divergent results are caused by a lack of consistency in the outcomes or whether the differ- ences can be explained by the impact of covariates that were ...BRAVO studies demon- ... See full document
25
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
... The efficacy of natalizumab and its impact on quality of life have also been studied in different clinical practice and real-life ...the efficacy of natalizumab in clinical trials might differ from the ... See full document
15
Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
... FREEDOMS. Compared with placebo, fingolimod showed a 48% relative reduction in relapse rates with the 0.5 mg dose and a 50% with the 1.25 mg dose. Instead, no relevant effect has been observed in 3-month or 6-month ... See full document
6
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
... DMF seems to interfere with cellular redox system by modulating intracellular thiols and thereby increasing the level of reduced glutathione. The major involved transcription factor in this process is nuclear factor ... See full document
14
Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?
... and Efficacy in Relapsing Remitting Multiple Sclerosis) and SENTINEL (Safety and Efficacy of Natalizumab in Combination with Inter- feron Beta-1a in Patients with ... See full document
6
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action
... the relapsing–remitting type (RRMS), which may initially present as a clinically isolated ...similarity, studies have identified distinct pathological differences 20 that could ... See full document
5
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
... explaining why immunologi- cal surveillance is substantially preserved during ...models studies have shown that fingolimod interacts with S1PR1, S1PR3, and S1PR5 expressed by neurons, astrocytes, ... See full document
7
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
... for relapsing remitting multiple ...high efficacy in several clinical ...in Multiple Sclerosis confirmed these ...the efficacy of alemtuzumab has been widely proven, ... See full document
73
The heritage of glatiramer acetate and its use in multiple sclerosis
... Multiple sclerosis (MS) is a chronic and progressively debilitating disease of the central nervous ...The efficacy of glatiramer acetate 20 mg/mL once daily as first-line treatment in ... See full document
67
Nuclear factor erythroid 2 related factor 2 is a critical target for the treatment of glucocorticoid resistant lupus nephritis
... The efficacy of oral DMF in the treat- ment of relapsing–remitting multiple sclerosis (RRMS) has been proven in two phase III studies: DEFINE (Deter- mination of the ... See full document
10
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
... progressive multiple sclerosis, had a history of peptic ulcer or current symptoms of dyspepsia, diabetes mellitus, alcohol or drug abuse, major depression, cardiac or renal insufficiency, or other serious ... See full document
76
Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study
... (cross-sectional) studies. Furthermore, a great amount of studies included were from Western countries, while only one study was from China and there is no relevant report about other Asian populations or ... See full document
15
Association of Human Herpesvirus 6 and 8 in Relapsing Remitting Multiple Sclerosis Type during Exacerbation
... other studies may denote a considerable rela- tion between exacerbation and HHVs, in addition to HHVs potential task in MS pathogenesis, plus all cases in this study had not receive any of beta-interferon drugs ... See full document
7
The MRZ reaction in primary progressive multiple sclerosis
... illustrates how inconsistent results of MRZR studies can appear if differences in definition (MRZR-2 ...lier studies [5, 10, 15, ...recent studies [22, 23]. Furthermore, several studies ... See full document
10
Therapeutic application of monoclonal antibodies in multiple sclerosis: focus on alemtuzumab
... promising agents for treatment of many diseases, and various types of mAbs have been evaluated for treatment of EAE and MS, especially for reducing relapse rates. Natalizumab was approved as the first mAb treatment for ... See full document
32
Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
... in multiple sclerosis, we initiated a prospective, observational, non- interventional study to monitor fatigue in treatment-naive RRMS patients initiating therapy with glatiramer acetate under conditions of ... See full document
23
Serum prolactin in patients with relapsing remitting multiple sclerosis
... two studies; the first one was done by Correale and colleagues 2014 [25], who studied the role of PRL in MS patients and its effect on B lympho- cytes; they reported that PRL induces CD40 expression in B cells and ... See full document
78
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosisThe MIRROR study
... Overall, this study demonstrates that ofatumumab has a high capacity to suppress new brain MRI lesions with subcutaneous administration at considerably lower (and incompletely B-cell depleting) doses compared with those ... See full document
8
Biomarkers of multiple sclerosis: current findings
... discovery studies in CIS patients comparing those who convert to MS to those who do ...to understand the reliability of predictive biomarkers and be able to identify subgroups of patients with a more severe ... See full document
8
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
... In summary, we have found in this study that levels of POP activity in plasma from RR-MS patients are substan- tially reduced compared with healthy controls (Fig. 2A). Analysing this data, we also find that there is a ... See full document
47
Related subjects